Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Distress Tolerance and Benzodiazepine Discontinuation in OAT
NCT04109118Phase 2Completed
- Sponsor
- Boston Medical Center
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Boston Medical Center. Primary endpoints: Participant Acceptability of the Interventions at 13 weeks and Number of Participants Who Rates the Intervention as Feasible at 13 weeks. Started Mar 2021; status: completed.
Beyond the preview
Go deeper on NCT04109118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109118.